Novavax (NASDAQ:NVAX) is scheduled to post its quarterly earnings results before the market opens on Monday, March 18th. Analysts expect Novavax to post earnings of ($0.12) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

NASDAQ NVAX opened at $0.51 on Friday. Novavax has a 1-year low of $0.49 and a 1-year high of $2.58. The company has a market capitalization of $201.30 million, a P/E ratio of -0.81 and a beta of 2.08.

Several equities analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Novavax in a research note on Friday, November 23rd. Piper Jaffray Companies downgraded Novavax from an “overweight” rating to an “underweight” rating in a research note on Thursday, February 28th. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a research note on Monday, January 7th. JPMorgan Chase & Co. downgraded Novavax from an “overweight” rating to an “underweight” rating in a research note on Thursday, February 28th. Finally, LADENBURG THALM/SH SH assumed coverage on Novavax in a research note on Tuesday, December 18th. They issued a “buy” rating and a $3.00 price objective for the company. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $3.50.

TRADEMARK VIOLATION NOTICE: “Novavax (NVAX) to Release Earnings on Monday” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/novavax-nvax-to-release-earnings-on-monday/2896071.html.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.

See Also: What is a stock buyback?

Earnings History for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.